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Abstract Objective: We describe a case of refractory myasthenia gravis with bulbar involvement and the nu-
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16077.
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doi:10.1016/j.nut.2008tritional treatment solutions proposed to treat the associated dysphagia and malnutrition.
Methods: A 39-y-old woman with refractory myasthenia gravis was referred to our clinical nutrition
unit for deteriorating dysphagia and progressive malnutrition.
Results: The first-line nutritional approach consisted of dietary counseling and thickened meals.
Unfortunately, no adequate oral intake was achieved and an enteral nutrition treatment was proposed.
A nasogastric tube was removed after a few days due to local pain and poor quality of life. Despite
consistent weight loss and overt malnutrition, the patient refused percutaneous endoscopic gastro-
stomy placement. Neurologic symptoms did not show any improvement but unexpectedly the patient’s
weight started to increase to previous values. Anamnestic recall revealed that the patient learned by
herself how to position the nasogastric tube that is now temporarily used for formula infusion coincid-
ing with neurologic pousse´s.
Conclusions: Current guidelines consider chronic neurologic diseases with associated dysphagia,
where refractory myesthania gravis has also been considered, a unique category. Chronic neurogenic
dysphagia with high risk of aspiration, long-term inability to obtain adequate oral intakes, and malnu-
trition are established indications for percutaneous endoscopic gastrostomy placement. However,
patients may need different forms of nutritional intervention during the course of their illness and
choices and indications should contemplate ethical reasons, clinical benefits, minimal risks, and ac-
ceptable quality of life.Minimally invasive intermittent enteral nutritionmight be considered a possible
clue for nutritional management of exacerbating dysphagia.  2009 Elsevier Inc. All rights reserved.Keywords: Myasthenia gravis; Dysphagia; Malnutrition; Enteral feeding; Percutaneous endoscopic gastrostomy; Qualityof lifeCase report
In April 2006, a 39-y-old woman was referred to our
clinical nutrition unit for deteriorating dysphagia and
malnutrition in the course of myasthenia gravis (MG) exac-
erbations. Her clinical history included Graves-Basedow
disease, uterine fibromyoma causing chronic anemia, anx-
ious-depressive syndrome, and other different neoplastic dis-
eases (squamous cell carcinoma of the soft palate, left-foot
melanoma, vocal chord polypus) that were treated withuthor. Tel.: þ39-02-503-16079; fax: þ39-02-503-
anuele.cereda@virgilio.it (E. Cereda).
front matter  2009 Elsevier Inc. All rights reserved.
.12.016a surgical procedure. MG (presence of acetylcholine recep-
tor-specific autoantibodies and a primary postsynaptic neuro-
muscular junctional disorder by electrophysiologic testing)
[1–3] was first diagnosed in August 2005. Computed tomo-
gram of the chest revealed the presence of mediastinal thymic
residuals. The patient was treated with oral anticholinesterase
therapy (pyridostigmine bromide) and a thymectomy was
performed (Table 1). Unfortunately, despite initial improve-
ment of neurologic manifestations, no long-lasting benefits
were achieved. The disease assumed a refractory course
with more and more frequent exacerbations that progres-
sively required increasing doses of immunosuppressant (cor-
ticosteroids followed by azathioprine), frequent visits for
plasmapheresis (in the case of a myasthenic crisis, about
Table 1
Anthropometric data, biochemical parameters, and treatments (pharmacologic and nutritional) during follow-up
August 2005 April 2006 July 2006 October 2006 January 2007 April 2007 August 2008
Weight (kg) 57 53.3 49.7 41.0 51.4 54.8 56.8
BMI (kg/m2) 25.0 23.3 21.8 17.9 22.5 24.0 24.9
WL (%) — 6.5 12.8 28.0 9.8 3.8 0.3
MUAC (cm)* — 29.2 (50) 24.5 (10–25) 20.1 (<5) 25.3 (10) 28.2 (25–50) 28.3 (25–50)
TSF (mm)* — 15.5 (10–25) 13.2 (5–10) 7.8 (<5) 15.1 (10–25) 19.6 (25–30) 18.8 (25–30)
AMA (cm2)* — 47.1 (w80) 32.9 (w25) 24.8 (<5) 33.6 (w25) 38.6 (50) 39.9 (55–60)
BP (mmHg) 135/85 120/80 105/70 90/65 110/70 110/75 120/80
Hb (g/L) 12,7 11.9 13.5 10.1 10.9 12 12.1
MCV (fL) — 77.3 73.5 63.9 65.5 70.6 76.5
TLC (/mm3) — 1650 1296 1028 1551 1989 1978
Iron (mg/dL) — 81 102 29 39 80 85
Albumin (g/L) — 44 41 35 40 42 41
TC (mg/dL) — 152 133 — 156 — 149
TG (mg/dL) — 75 64 — 74 — 78
Glucose (mg/dL) — 88 80 85 86 92 89
Prevalent neurologic
symptoms
(new onset)
Weakness, anserine
gait, asymmetric
ptosis, chewing and
swallowing
difficulties
Bulbar weakness
with hoarseness,
nasal speech
and liquid dysphagia
Dysarthria, total
dysphagia,
with nasal
regurgitation
Neck flexor
weakness,
marked
limb weakness,
smaller lung
volumes
Assisted walking,
diplopia
weakness,
hypophonia,
dyspnea
Increased susceptibility to exacerbations
despite in-course treatments
Pharmacologic
treatment
of myasthenia
Pyridostigmine
bromide
300 mg
þ 180R/d/
Pyridostigmine
bromide
450 mgþ
180R/d/
Pyridostigmine
bromide
555 mgþ
180R/d/
Pyridostigmine
bromide
300 mg
þ 180R/d/
As previous/ As previous/ As previous
Thymectomy
performed
in January
2006
þ
Steroids
50 mg/d/
Steroids
75 mg/d/
Steroids
50 mg/d/
As previous/ Steroids 75 mg/d/ Steroids
75 mg/d
þ
PE/3 mo/ As previous/ As previous/ As previous/ As previous/ As previous
þ
Ig-IV/3 mo As previous/ As previous/ Ig-IV/2 mo As previous/ Monthly
þ
Azathioprine
150 mg/d
As previous/ As previous/ As previous
þ
Inhaled broncho-
dilator 23/d
As previous/ As previous
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E. Cereda et al. / Nutrition 25 (2009) 1067–1072 1069every 3 mo), and the use of regular intravenous immunoglob-
ulins (Ig-IV) that the patient currently uses once a month (for
disease course and treatment adjustments, see Table 1). Up to
January 2006, body weight was stable (57 kg, body mass in-
dex [BMI] 25 kg/m2) and simple dietary advice (for a ‘‘soft’’
diet) showed efficacy in coping with chewing and swallow-
ing difficulties. The more consistent bulbar involvement
led to liquid followed by total dysphagia. At admission
(April 2006) to our unit significant weight loss (w6.5% in
the previous 3 mo) was already recordable. In the first in-
stance, the use of oral nutritional supplements and of thicken-
ing agents was prescribed but the rapid worsening of both
clinical conditions (further 6% weight loss) and neurologic
symptoms and the high risk of aspiration indicated enteral
nutrition (July 2006) [4–7]. Accordingly, a nasogastric tube
was positioned and home delivery of the infusion equipment
was planned. Initial therapy consisted of an infusion of
1000 mL of a polymeric hypercaloric formula (1.5 kcal/
mL; w1500 kcal/d [30 kcal$kg1$d1]). In agreement with
the patient, the choice of this type of support was made to ob-
tain effective nutritional repletion and to maintain an accept-
able quality of life (QOL). After an adequate period of enteral
nutrition induction, with a progressive increase of the amount
of formula to be infused hourly, overall support was planned
to take place during the night, thus allowing for good man-
agement of activities of daily living. However, after a few
days the tube was removed due to poor toleration. The patient
complained of a local pain in the inner nose and above all the
‘‘unacceptable prospect of constantly appearing to have
a trunk.’’ Then overt malnutrition occurred (October 2006,
BMI 17,9 kg/m2, total weight loss 28% of initial body
weight) and different, but not life-threatening, episodes of as-
piration with cough were reported. A percutaneous endo-
scopic gastrostomy was proposed but was refused. She
could not accept ‘‘the presence of a foreign body’’ and to
have a constant sign of her disease even in period of fair com-
pensation (under therapeutic control). Neurologic symptoms
did not show any improvement but unexpectedly the pa-
tient’s weight started to increase to previous values and,
only after 6 mo, anamnestic recall revealed that the patient
learned by herself how to position the nasogastric tube and
to feed. In particular, she modified the positioning technique
as follows: she introduced a lubricated (petroleum oil) 12-Fr
feeding tube in the nose until she felt it touching the throat.
Then she pushed it while swallowing to introduce it until
the mark was reached but without checking the correct place-
ment (e.g., aspiration of a sample of gastric content and
a check of the pH with a litmus paper). The patient opted
for overnight feeding (1000 mL of a polymeric hypercaloric
formula, up to 140 mL/h from 13:00 to 07:00 h,
w35 kcal$kg1$d1) and to remove the tube at the end of
each infusion. In addition, she refused our assistance but ac-
cepted advice on how to check the correct placement. From
January 2007 to August 2008 she positioned the feeding tube
for about 7–10 d/mo according to disease exacerbations, thus
maintaining her weight for about 8 mo (January 2008 to
Fig. 1. Hypothetical decision tree for nutritional treatment of MG and neurogenic dysphagia [6]. MG, myasthenia gravis.
E. Cereda et al. / Nutrition 25 (2009) 1067–10721070August 2008; for the course of nutritional, anthropometric,
and biochemical parameters, see Table 1).
Given the current frequency of plasmapheresis and Ig-IV
cycles, placement of a deep central venous catheter to admin-
ister the treatments has been considered and the use of total
parenteral nutrition might be hypothesized. However, the pa-
tient’s acceptance and the actual feasibility of the procedure
have not yet been tested.
Discussion
Myesthenia grave is a rare (prevalence 1–2 in 5000) auto-
immune disease of the neuromuscular junction due to the
presence of acetylcholine receptor-specific or muscle-
specific tyrosine kinase autoantibodies, which translates to
the typical weakness and fatigue [1–3].
With regard to clinical presentation, in about two-thirds of
patients, the initial deficit involves extrinsic ocular muscles
but in only 10% of cases do symptoms remain limited to
this area (ocular MG). Usually, fluctuating and fatigable
weakness progressively generalizes to other muscle groups
until the occasional lethal involvement of the respiratory
muscle group. Bulbar muscles can also be affected. In such
a case, oropharyngeal weakness results in a fall of the soft
palate with nasal speech and possible liquid regurgitation
during swallowing or overt dysphagia, whereas laryngeal in-
volvement is associated with hoarseness, dysarthria, incom-plete glottic closure, and an increased risk of aspiration. In
any case, the evolution, even in relation to different responses
to available treatments, is unpredictable, thus passing from
mild and reversible to a refractory disease condition with
occasional or regular exacerbations as in the present case.
Accordingly, treatment must be individualized to obtain
maximum improvement of neuromuscular function and
minimum adverse effects and take into account a patient’s
ability to comply with drug use and doses [3,8].
However, not only pharmacologic but also nutritional
treatments should be considered in disease management,
but, so far, little attention seems to be given to this issue.
Poor nutritional status, as described by a lowBMI andmuscle
protein (arm muscle area) and body weight losses, is consis-
tently associated with adverse outcomes (e.g., mortality, in-
fections) and chronic neurologic diseases are know to
negatively affect adequate energy intake [5,6]. Indeed, there
is no study describing possible changes of nutritional status
in patients with MG. In addition, it was inappropriate to in-
clude MG among chronic neurologic diseases in which the
final treatment is frequently percutaneous gastrostomy
[5–7]. Nevertheless, nutritional treatment also should be indi-
vidualized according to pharmacologic treatment response.
Patients may need different forms of nutritional intervention
(Fig. 1) during the course of their illness and choices and in-
dications should contemplate nutritional risk, ethical reasons,
adequate clinical benefits, minimal risks, and an acceptable
E. Cereda et al. / Nutrition 25 (2009) 1067–1072 1071QOL [6,7,9]. This might be emphasized for MG in which
neurologic symptoms with nutritional aspects present and
progress differently from one case to another. Further, other
overlapping conditions might affect a patient’s swallowing
ability (e.g., Graves-Basedow disease, squamous cell carci-
noma of the soft palate, and vocal cord polyp) and interest
in food (e.g., depression) and should be taken into account
during a patient’s assessment. Moreover, although the refrac-
tory form seems like an irreversible disease, the course is gen-
erally a pousse´s, with exacerbations alternating with periods
of fair compensation resulting from cycles of plasmapheresis
and Ig-IV.
In the initial stages, patients might present only mild chew-
ing difficulties due to closure muscle weakness and fatigabil-
ity, and the use of consistency-modified diets or the choice
of certain food rather than others and compensatory postures
of the headmay be sufficient to remedy the problem [7]. More-
over, the use of oral nutritional supplements should always be
considered when protein–calorie needs are not reached and/or
nutrition-related risk is recorded [4,10]. In other cases, overt
dysphagia might be the next step or occur from the outset or
be the only isolated symptom [11]. This condition is currently
recognized as manageable and, when effective management is
implemented, an improved QOL can result. In this regard, ad-
equate diagnosing is least beneficial and different techniques
are currently available. When motor and non-motor disorders
are suspected, manometry, fiber-optic endoscopy, and electro-
myography are valid assessment tools, are widely available in
a hospital setting, and should be regarded as complementary
[7,12,13]. However, despite being effective and accurate, vid-
eofluorography and videofluoroscopy with concomitant Ten-
silon testing are less available, more expensive, require
trained personnel, and have been found to be unsuitable for
routine use due to radiation exposure [7,11]. The potential
value of novel techniques, such as scintigraphy, impedance
pharyngography, or simple acoustic devices, has never been
investigated in subjects with MG.
When prevalent liquid dysphagia is detected, the most
important potential consequences are dehydration and aspira-
tion. Accordingly, the use of jelly-water allows the mainte-
nance of a positive body–water balance, QOL, and lower
risk of aspiration. However, when solid/complete dysphagia
occurs, consistent protein–calorie deficit and subsequent mal-
nutrition also should be considered. In the present case, consis-
tent weight loss (>10% in the previous 3 mo) toward
malnutrition (BMI<18.5 kg/m2) and evident alteration of nu-
tritional markers (e.g., albumin level <35 g/L, total lympho-
cyte count <1500/mm3) clearly suggested a high risk of
nutrition-related health complications [14] (Table 1). In such
a case, thanks to the efforts of commercial clinical nutrition
companies, safe and effective nutritional repletion can be ini-
tially achieved not only through a consistency-modified diet
and thickened meals but also through the use of whole formu-
lations and ready-to-eat foods that retain the appearance and
flavor of the original and enable food enjoyment and QOL
to be addressed [7]. In contrast, chronic neurogenic dysphagiawith a high risk of aspiration, a long-term inability to obtain
adequate oral intakes, and concomitant malnutrition are the
most common and established indications for gastrostomy
[5,6] but ‘‘. prior to the insertion of an enteral feeding
tube, each case should be considered on its own merits, taking
into account the clinical situation, diagnosis, prognosis, ethical
issues, the expected effect on the patient’s quality of life and
the patient’s own wishes.’’[6]. The present case is a good
example to reflect on the application of guidelines. Indeed,
a patient’s willingness is out of the question. However, the
clinical situation and QOL become a matter for discussion.
Although placement of a gastrostomy tube would have offered
consistent clinical benefits, our experience demonstrates that
in refractory MG the typical nutritional approach usually re-
garded for the majority of chronic neurologic diseases may
sometimes be too aggressive. Thus, in agreement with the eth-
ical issue, all options available to us must be considered. Even-
tually, also an intermittent enteral nutrition (e.g., for 10 d) that
appears to be effective and suitable for a pousse´s chronic dis-
ease inwhich the initial drug response allows a patient tomain-
tain food enjoyment and QOL until the next exacerbation.
Unfortunately, current guidelines consider chronic neurologic
diseases with associated dysphagia, where refractory MG has
also been considered, a unique category and gastrostomy as
been indicated [4,6]. However, we believe that in MG QOL
could be maintained longer and with higher values than those
of other irreversible disorders (e.g., bulbar paralysis, cerebral
palsy, amyotrophic lateral sclerosis, brain tumor,multiple scle-
rosis, Alzheimer’s and Parkinson’s diseases). In addition, in-
termittent enteral nutrition is no longer contemplated [4,6],
probably in relation to major limitations such as monitoring,
compliance, and safety.
In some cases, if a central venous catheter is available for
other purposes (e.g., plasma exchange and/or Ig-IV cycles),
parenteral nutrition also might be considered to provide nutri-
tional support but major complications associated with its use
and the need for proper care of this route should be always
kept in balance [4,15].
However, despite appearing feasible by highly compliant
patients andwith manual skills, the self-positioning of a naso-
gastric tube is a practice that should be probably discouraged
in view of the high risk of incorrect placement (e.g., airways
or too high in the esophagus) and aspiration, with subsequent
ingested pneumonia.
Although this practice would not probably sound new to
clinical nutritionists, including ourselves, to the best of our
knowledge, this is the first case to be reported in the literature.
Timely multidisciplinary (neurologic and nutritional) ap-
proaches to a patient with chronic neurologic diseases is
strongly recommended.
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